Methylene Blue

Book Appointment

What is Methylene Blue and What Are Some of the Reasons to Consider it?

Methylene Blue was first approved for use in Medicine as a stain in 1876. It is one of the most repurposed drugs available and currently FDA approved to treat malaria, septic shock, cyanide poisoning and methemoglobinemia. 

Methylene Blue has been found to have superior properties to support cognitive function, improved focus, attention, and energy, but also carries with it long term neuroprotective benefits. It has been used around the world to treat Covid-19 infection as well as other bacterial, viral and fungal infections. 

 It is also showing promise in treating Parkinson’s Disease, Alzheimer’s Disease, Mood Disorders, and topically to treat severe acne and toenail fungal infection.

Viral Treatment

Methylene Blue is believed to have several mechanisms of action that may contribute to enhanced mitochondrial function for improved overall cell health. Additionally, its antioxidant properties can help neutralize harmful free radicals that can damage cells and accelerate aging.

Methylene Blue has also been found to help in treating Covid-19 infection by

  • Reduced Viral Replication
  • Reduced Viral Entry
  • Photo-oxidative Viral Entry
    (Increase effectiveness when combined with dry salt and red-light therapy)
  • Reduced Hypoxia
  • Reduced Cytopathic Effects
  • Helps combat chronic pain and fatigue
  • Broad Spectrum Antimicrobial
    (Bacterial/Viral/Fungal/Other viruses) reducing secondary infections

How is Methylene Blue taken?

Methylene Blue can either be taken orally, through IV infusions or applied topically.

Does Methylene Blue Require a Prescription?

Yes, Methylene Blue does require a prescription. Click here to schedule an appointment with our Certified Family Nurse Practitioner to see if Methylene Blue is right for you.

References
  • Dabholkar et al., 2021 outlined that Methylene Blue ameliorates COVID-19 at every
  • pathophysiological state
  • Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of
  • methylene blue in manic-depressive psychosis. Biol Psychiatry. 1986;21(10):915-920.
  • doi:10.1016/0006-3223(86)90265-9
  • Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau
  • aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996;93(20):11213-11218. doi:10.1073/pnas.93.20.11213
  • Fesharaki-Zadeh A, Lowe N, Arnsten AFT. Clinical experience with the α2A-adrenoceptor agonist, guanfacine,
  • and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports.
  • 2023;3:100154. doi: 10.1016/j.nerep.2022.100154. Epub 2022 Nov 25. PMCID: PMC9691274.